title: Relapsed acute myeloid leukemia: why is there no standard of care?
abstract: Relapse after achieving a prior response remains one of the most important obstacles to improving the outcome of patients with acute myeloid leukemia (AML). Although overall, the majority of patients with disease relapse do poorly, this is by no means uniform and a number of predictors of outcome have been identified. Previously, most trials of investigational agents in the setting of disease relapse in AML have accrued a wide range of patients with widely different patient and disease characteristics. With increased understanding of the biology of the neoplastic change in AML, and better identification of disease subsets based on their molecular characterization, target-specific novel agents are being developed that will hopefully lead to better strategies, not only for treating relapsed disease, but also for the initial induction treatment.
authors.affiliation: Department of Leukemia, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA. Electronic address: fravandi@mdanderson.org.
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols; D003561:Cytarabine / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D059039:Standard of Care; D016019:Survival Analysis; D014184:Transplantation, Homologous
chemical_list: D018943:Anthracyclines; D003561:Cytarabine
keywords: acute myeloid leukemia; biology; relapse; targeted therapy